Nociceptin/Orphanin Phenylalanine Glutamine (FQ) Receptor and Cardiovascular Disease

Cardiovascular Therapeutics

Volumn 29, Issue 1, 2011, Pages 23-28

  Armstead, William M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cerebral ischemia; Nociceptin; Opioids; Signaling; Stroke; Traumatic brain injury

Indexed keywords

NOCICEPTIN ORPHANIN PHENYLALANINE GLUTAMINE; NOCICEPTIN ORPHANIN PHENYLALANINE GLUTAMINE RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; VASODILATOR AGENT;

BRAIN ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STROKE; TRAUMATIC BRAIN INJURY; VASODILATATION;

AMINO ACID SEQUENCE; ANIMALS; BRAIN INJURIES; CARDIOVASCULAR DISEASES; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; MOLECULAR SEQUENCE DATA; NEUROTRANSMITTER AGENTS; RECEPTORS, OPIOID;

EID: 78751486385     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00241.x     Document Type: Review

References (71)

1. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupld receptor. Science 1995;270:792-794.
2. 1 receptor. Nature 1995;377:532-535.
3. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta, or kappa opioid receptor type. FEBS Lett 1994;347:284-288.
4. Vaughan CW, Ingram SL, Christie MJ. Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 1997;17:996-1003.
5. Connor M, Christie MJ. Modulation of Ca channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol 1998;509:47-58.
6. Schlicker E, Morari M. Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 2000;21:1023-1029.
7. Guerrini R, Calo G, Rizzi A, et al. A new selective antagonist of the nociceptin receptor. Br J Pharmacol 1998;123:163-165.
8. Wei Y, Ouyang D, Liu Y, Chang Z, Tang J, Ding J. Peripheral tissue distribution of orphanin FQ precursor mRNA in stroke prone spontaneously hypertensive rats. Chin Med Sci J 1999;14:67-70.
9. 4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol 2003;482:17-23.
10. Gumusel B, Hao Q, Hyman A, Chang JK, Kapusta DR, Lippton H. Nociceptin: An endogenous agonist fro central opioid like 1 (ORL1) receptors possesses system vasorelaxant properties. Life Sci 1997;60:PL141-PL145.
11. Hugghins SY, Champion HC, Cheng C, Kadowitz PJ, Jeter JR Jr. Vasorelaxant responses to endomorphins, nociceptin, albuterol, and adrenomedullin in rat aorta. Life Sci 2000;67:471-476.
12. Xu PH, Chang M, Cheng LX, Cheng Q, Yan X, Wang R. The relaxant effect of nociceptin on porcine coronary arterial ring segments. Can J Physiol Pharmacol 2004;82:993-999.
13. Champion HC, Pierce RL, Kadowitz PJ. Nociceptin, a novel endogenous ligand for the ORL1 receptor, dilates isolated resistance arteries from the rat. Regul Pept 1998;78:69-74.
14. Champion HC, Czapla MA, Kadowitz PJ. Nociceptin, an endogenous ligand for the ORL1 receptor, decreases cardiac output and total peripheral resistance in the rat. Peptides 1997;18:729-732.
15. Kapusta DR, Sezen SF, Chang JK, Lippton H, Kengis VA. Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci 1997;60:PL15-PL21.
16. Giuliani S, Tramontana M, Lecci A, Maggi CA. Effect of nociceptin on heart rate and blood pressure in anesthetized rats. Eur Pharmacol 1997;333:177-179.
17. Lin B, Waterman R, Lippton H. Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. Life Sci 2000;66:PL99-PL104.
18. Champion HC, Bivalacqua TJ, Friedman DE, Zadina JE, Kastin AJ, Kadowitz PJ. Nitric oxide release mediates vasodilator responses to endomorphin 1 but not nociceptin/OFQ in the hindquarters vascular bed of the rat. Peptides 1998;19:1595-1602.
19. Doggrell SA. Cardiovascular and renal effects of nociceptin/orphanin FQ: A new mediator to target? Curr Opin Invest Drugs 2007;8:742-749.
20. Arndt ML, Wu D, Soong Y, Szeto HH. Nociceptin/orphanin FQ increases blood pressure and heart rate via sympathetic activation in sheep. Peptides 1999;20:465-470.
21. Salis MB, Emanueili C, Milia AF, Guerrini R, Madeddu P. Studies of the cardiovascular effects of nociceptin and related peptides. Peptides 2000;21:985-993.
22. Kapusta DR. Neurohumoral effects of orphanin FQ/nociceptin: Relevance to cardiovascular and renal function. Peptides 2000;21:1081-1099.
23. 4 receptors in the regulation of the cardiovascular system. J Physiol Pharmacol 2002;53:301-324.
24. Giuliani S, Maggi CA. Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea pig left atrium. Eur J Pharmacol 1997;332:231-236.
25. Bucher B. ORL1 receptor-mediated inhibition by nociceptin of noradrenaline release from perivascular sympathetic nerve endings of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol 1998;358:682-685.
26. Lawrence AJ, Jarrott B. Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Prog Neurobiol 1996;48:21-53.
27. Mao L, Wang JQ. Microinjection of nociceptin (orphanin FQ) into nucleus tractus solitarii elevates blood pressure and heart rate in both anesthetized and conscious rats. J Pharmacol Exp Ther 2000;294:255-262.
28. Chu X, Xu N, Li P, Mao L, Wang JQ. Inhibition of cardiovascular activity following microinjection of novel opioid-like neuropeptide nociceptin (orphanin FQ) into the rat rostral ventrolateral medulla. Brain Res 1999;829:134-142.
29. Chitravanshi VC, Sapru HN. Microinjections of nociceptin into the nucleus ambiguous elicits tachycardia in the rat. Brain Res 2005;1051:199-204.
30. Venkatesan P, Baxi S, Evans C, Neff R, Wang X, Mendelowitz D. Glycinergic inputs to cardiac vagal neurons in the nucleus ambiguous are inhibited by nociceptin and μ-selective opioids. J Neurophysiol 2003;90:1581-1588.
31. Kapusta DR, Kenigs VA. Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. Am J Physiol 1999;277:R987-R995.
32. Jansco G, Jansco-Gabor A, Szolcsanji J. Direct evidence for neurogenic inflammation and its prevention by denervation and pretreatment with capsaicin. Br J Pharmacol 1967;31:138-151.
33. Zhang C, McDougall JJ. Stimulation of sensor neuropeptide release by nociceptin/orphanin FQ leads to hyperaemia in acutely inflamed rat knees. Br J Pharmacol 2006;148:938-946.
34. Brooks ZLS, Stedman E, Guerrini R, Lawton BK, Calo G, Lambert DG. Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. AJP 2007;293:H2977-H2985.
35. Helyes Z, Nemeth J, Pinter E, Szolcsanyi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 1997;121:613-615.
36. Nemeth J, Helyes Z, Oroszi G, Than M, Pinter E, Szolcsanyi J. Inhibition of nociceptin on sensory neuropeptide release and mast cell-mediated plasma extravasation in rats. Eur J Pharmacol 1998;347:101-104.
37. ca channel activation. Brain Res 1999;835:315-323.
38. Armstead WM. Relationship between nociceptin/orphanin FQ and cerebral hemodynamics following hypoxia/ischemia in piglets. Am J Physiol 2000;278:H477-H483.
39. Volpe JJ. Brain injury in the premature infant: Overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 1998;5:135-151.
40. Leffler CW, Busija DW, Mirro R, Armstead WM, Beasley DG. Effects of ischemia on brain blood flow and oxygen consumption of newborn pigs. Am J Physiol 1989;257:H1917-H1926.
41. Leffler CW, Busija DW, Beasley DG, Armstead WM, Mirro R. Postischemic microvascular cerebral responses to norepinephrine and hypotension in newborn pigs. Stroke 1989;20:541-546.
42. Leffler CW, Busija DW, Armstead WM, Mirro R, Beasley DG. Ischemia alters cerebral vascular responses to hypercapnia and acetylcholine in piglets. Ped Res 1989;25:180-183.
43. Armstead WM. Altered release of prostaglandins contributes to hypoxic/ischemic impairment of NOC/oFQ cerebrovasodilation. Brain Res 2000;859:104-112.
44. Armstead WM. cGMP and cAMP in prostaglandin induced pial artery dilation and increased CSF opioid concentration. Am J Physiol 1996;271:H166-H172.
45. + channel dependent mechanisms in piglet hypoxic/ischemic impaired nociceptin/orphanin FQ induced cerebrovasodilation. Brain Res 2000;884:51-58.
46. Laudenbach V, Calo G, Guerrini R, Lamboley G, Benoist JF, Evrard P, Gressens P. Nociceptin/orphanin FQ exacerbates excitotoxic white matter lesions in the murine neonatal brain. J Clin Invest 2001;107:457-466.
47. Busija DW, Meng W, Bari F, McGough S, Errico RA, Tobin JR, Louis TM. Effects of ischemia on cerebrovascular responses to N-methyl-D-aspartate in piglets. Am J Physiol 1996;270:H1225-H1230.
48. Armstead WM. NOC/oFQ contributes to hypoxic/ischemic impairment of N-methyl-D-Aspartate-induced cerebral vasodilation. Brain Res 2000;868:48-55.
49. Nicol B, Lambert DG, Rowbotha DJ, Smart D, McKnight At. Nociceptin induced inhibition of K evoked glutamate release from rat cerebrocortical slices. Br J Pharmacol 1996;189:1081-1083.
50. Faber ESL, Chambers JP, Evans R, Henderson G. Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br J Pharmacol 1996;189:189-190.
51. Armstead WM. NOC/oFQ PKC dependent superoxide generation contributes to hypoxic/ischemic impairment of NMDA cerebrovasodilation. Am J Physiol 2000;279:H2678-H2684.
52. Philip S, Armstead WM. Newborn pig nociceptin/orphanin FQ activates protein tyrosine kinase and mitogen activated protein kinase to impair NMDA cerebrovasodilation after ischemia. Neuro Report 2003;14:201-203.
53. Armstead WM. NOC/oFQ and NMDA contribute to piglet hypoxic ischemic hypotensive cerebrovasodilation impairment. Ped Res 2002;51:586-591.
54. Armstead WM. NOC/oFQ activates PKC and generates superoxide to impair hypotensive cerebrovasodilation after hypoxia/ischemia. Med Sci Monit 2002;8:BR8-BR14.
55. Jagolino AL, Armstead WM. Nociceptin/orphanin FQ contributes to hypoxic ischemic impairment of hypercapnic cerebrovasodilation. Brain Res Bulletin 2001;55:465-468.
56. Jagolino AL, Armstead WM. PTK, MAPK, and NOC/oFQ impair hypercapnic cerebrovasodilation after hypoxia/ischemia. Am J Physiol 2003;284:H101-H107.
57. Rodriguez JG. Childhood injuries in the United States. A priority issue. Am J Dis Child 1990;144:625-626.
58. Wei EP, Dietrich WD, Povlishock JT, Navari RM, Kontos HA. Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats. Circ Res 1980;46:37-47.
59. Gennarelli TA. Animate models of human head injury. J Neurotrauma 1994;11:357-368.
60. Armstead WM. Role of nociceptin/orphanin FQ in age dependent cerebral hemodynamic effects of brain injury. J Neurotrauma 2000;17:751-764.
61. Armstead WM. Role of altered cyclooxygenase metabolism in impaired cerebrovasodilation to nociceptin/orphanin FQ following brain injury. Brain Res Bulletin 2000;53:807-812.
62. Armstead WM. NOC/oFQ contributes to age dependent impairment of NMDA induced cerebrovasodilation after brain injury. Am J Physiol 2000;279:H2188-H2195.
63. Kulkarni M, Armstead WM. Superoxide generation links nociceptin/orphanin FQ (NOC/oFQ) release to impaired N-methyl-D-aspartate cerebrovasodilation after brain injury. Stroke 2000;31:1990-1996.
64. Kulkarni M, Armstead WM. Relationship between NOC/oFQ, dynorphin, and COX-2 activation in impaired NMDA cerebrovasodilation after brain injury. J Neurotrauma 2002;19:965-973.
65. Armstead WM. Influence of brain injury on vasopressin induced pial artery vasodilation: Role of superoxide anion. Am J Physiol 1996;70:H1272-H1278.
66. Armstead WM. Age dependent vasopressinergic modulation of NOC/oFQ induced impairment of NMDA cerebrovasodilation after brain injury. J Neurotrauma 2001;18:615-623.
67. Armstead WM. Role of endothelin-1 in age dependent cerebrovascular hypotensive responses after brain injury. Am J Physiol 1999;277:H1884-H1894.
68. Armstead WM. Age dependent endothelin contribution to NOC/oFQ induced impairment of NMDA cerebrovasodilation after brain injury. Peptides 2001;22:39-46.
69. Armstead WM. Age dependent NMDA contribution to impaired cerebral hemodynamics following brain injury. Develop Brain Res 2002;139:19-28.
70. ca channel activation. Brain Res 1999;816:158-164.
71. ca channel impairment after brain injury. Brain Res 2002;943:276-282.